Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Bank of America raised their price target on the stock from $307.00 to $314.00. Bank of America currently has a buy rating on the stock. Alnylam Pharmaceuticals traded as high as $289.67 and last traded at $287.99, with a volume of 518055 shares traded. The stock had previously closed at $283.32.
A number of other research firms also recently commented on ALNY. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Leerink Partners lifted their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday, June 25th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Six analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $285.95.
View Our Latest Analysis on ALNY
Insider Transactions at Alnylam Pharmaceuticals
Institutional Trading of Alnylam Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Swedbank AB increased its holdings in shares of Alnylam Pharmaceuticals by 160.3% in the third quarter. Swedbank AB now owns 53,729 shares of the biopharmaceutical company’s stock worth $14,777,000 after acquiring an additional 33,090 shares in the last quarter. Creative Planning grew its position in shares of Alnylam Pharmaceuticals by 24.6% in the 3rd quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock valued at $2,754,000 after purchasing an additional 1,978 shares during the period. Exchange Traded Concepts LLC increased its stake in Alnylam Pharmaceuticals by 4.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 3,568 shares of the biopharmaceutical company’s stock worth $981,000 after purchasing an additional 136 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Alnylam Pharmaceuticals by 400.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,000 shares of the biopharmaceutical company’s stock worth $275,000 after buying an additional 800 shares during the period. Finally, Tobam lifted its stake in Alnylam Pharmaceuticals by 5.8% in the third quarter. Tobam now owns 31,467 shares of the biopharmaceutical company’s stock valued at $8,654,000 after buying an additional 1,736 shares in the last quarter. 92.97% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Stock Up 1.4 %
The company’s fifty day moving average price is $269.96 and its two-hundred day moving average price is $214.43. The company has a market cap of $36.35 billion, a price-to-earnings ratio of -107.22 and a beta of 0.39.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same quarter in the previous year, the firm posted ($2.21) EPS. The company’s revenue was up 107.0% on a year-over-year basis. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Investing In Preferred Stock vs. Common Stock
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Health Care Stocks Explained: Why You Might Want to Invest
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.